Volume 28, Number 8—August 2022
Research
Increasing and More Commonly Refractory Mycobacterium avium Pulmonary Disease, Toronto, Ontario, Canada
Daan Raats1
, Sarah K. Brode, Mahtab Mehrabi, and Theodore K. Marras
, Sarah K. Brode, Mahtab Mehrabi, and Theodore K. Marras
Table 2
NTM disease characteristics of patients with Mycobacterium avium and M. xenopi pulmonary disease, Toronto, Ontario, Canada*
| Characteristic | M. avium |
M. xenopi |
|||||
|---|---|---|---|---|---|---|---|
| Early period, n = 82 |
Late period, n = 138 |
p value | Early period, n = 24 |
Late period, n = 8 |
p value | ||
| Previous NTM treatment† | |||||||
| Same species | 10 (12.2) | 23 (16.7) | 0.47 | 2 (8.3) | 1 (12.5) | Referent | |
| Any species | 12 (14.6) | 27 (19.6) | 5 (20.8) | 2 (25.0) | |||
| History of positive AFB smear |
53 (64.6) |
112 (81.2) |
0.01 |
13 (54.2) |
5 (62.5) |
Referent |
|
| CT pattern | |||||||
| Nodular-bronchiectatic | 60 (73.2) | 89 (64.5) | 0.33 | 7 (29.2) | 1 (12.5) | 0.07 | |
| Fibrocavitary | 17 (20.7) | 34 (24.6) | 16 (66.7) | 4 (50.0) | |||
| Other |
5 (6.1) |
15 (10.9) |
1 (4.2) |
3 (37.5) |
|||
| CT cavitation, any size |
33 (40.2) |
57 (41.3) |
0.89 |
18 (75.0) |
4 (50.0) |
0.22 |
|
| Median time from initial visit to treatment initiation, mo (IQR) | 1.5 (–15.3 to 17.5) | 0.0 (–5.0 to 9.0) | 0.39 | 0.5 (–8.5 to 17.3) | 0.5 (–1.0 to 3.75) | 0.91 | |
*Values are no. (%) except as indicated. Bold indicates significance. AFB, acid-fast bacilli; CT, computed tomography; IQR, interquartile range; NTM, nontuberculous mycobacteria. †All except 1 M. avium patient with previous treatment history had a record of a single previous treatment episode; all M. xenopi patients with previous treatment history had a record of a single previous treatment episode. P values compare previous treatment for any species
1Current affiliation: Ziekenhuis Oost-Limburg, Genk, Belgium.
Page created: June 14, 2022
Page updated: July 20, 2022
Page reviewed: July 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.